Abstract:Pancreatic ductal adenocarcinoma (PDAC) has poor survival outcomes. The main reasons include late presentation, resulting in only 20% of patients being eligible for surgery, and poor response to chemotherapy, secondary to the challenging tumour biology (1,2). For patients undergoing surgery, the local anatomy and invasiveness of PDAC results in high operative risks, with morbidity and mortality estimated at 50-70% and 2-8%, respectively (3,4). The incidence of PDAC is rising, making it the fourth leading cause of death in the United States (5). It is imperative to prioritise PDAC research. Technological advances may improve patient outcomes through early detection and optimisation of treatments. The editorial highlights the latest technological advances in PDAC and identifies areas for research.Technological breakthroughs enabling early detection of PDAC were described in a review on liquid biopsy (6). This sampling method uses biomarkers such as circulating tumour DNA (ctDNA) and extracellular vesicles (EVs). Liquid biopsy is exciting due to its non-invasive, real-time and repeatable properties. Recent advances in methylation analysis, detecting epigenetic reprogramming in early tumorigenesis, have improved the detection of PDAC using ctDNA. A meta-analysis performed in 2019 showed sensitivity and specificity rates of 70% and 86% respectively. Another biomarker showing promise are EVs, with one study showing high sensitivity and specificity rates of 99% and 82% respectively. The current accuracy of liquid biopsy across all methods for PDAC was investigated in a meta-analysis (7). They concluded that liquid biopsy using biomarkers such as ctDNA was less accurate than CA19-9 for PDAC detection. However, ctDNA was associated with worse survival, making it a useful prognostication tool. Further research utilising multiple biomarkers may increase the accuracy in PDAC detection.Advances in neoadjuvant chemotherapy regimens are enabling surgical treatment for patients with locally advanced PDAC. Zhang et al. documented the case of a patient with a locally advanced PDAC (8). Following six cycles of GEM-NabP chemotherapy the patient underwent surgery, with histology confirming near-complete response. Successes such as this are often attributed to favourable biology, but standardisation of neoadjuvant regimens may improve overall outcomes. Further improvements in neoadjuvant treatments are seen in combination with immunotherapy. Lu and colleagues published a case report of combined neoadjuvant treatment using a programmed cell death protein-1 inhibitor and chemoradiotherapy (9). Following neoadjuvant treatment for a locally advanced PDAC, the patient underwent a pylorus-preserving pancreaticoduodenectomy (PPPD) with histology showing a pathologic complete response.Further data is also showing the benefit of established adjuvant chemotherapy regimens. A retrospective cohort study by Choi and colleagues analysed outcomes for patients who received adjuvant chemotherapy for locally advanced PDAC (10). They showed that 5-fluorouracil-based regimens resulted in favourable survival. New advances have also been made in the delivery of chemotherapy. Cao et al. performed a meta-analysis of regional intra-arterial chemotherapy (RIAC) compared with systemic treatment (11). RIAC has been developed recently and trialled in PDAC due to its ability to deliver high concentrations locally, while maintaining low systemic drug levels. Their analysis concluded that patients who received RIAC had a higher rate of partial remission and fewer complications. The studies highlighted show progress within chemotherapy and immunotherapy. There is an urgent need for standardisation of regimens, combination therapy and drug delivery.Technological advances in radiotherapy (RT) for PDAC were highlighted in a review article by Malla et al (12). Despite the ability to convert borderline resectable cases to surgical resection, up to a third of patients can die during RT from disease progression. Advances in Stereotactic Body Radiation Therapy (SBRT) and hypofractionation enable the delivery of biologically effective doses with reduced toxicity to surrounding tissues. Specifically, innovation in magnetic resonance-guided on-table adaptive RT is enabling this. A recent phase two trial demonstrated reduced incidence of acute grade 3+ gastrointestinal toxicity at 90 days post treatment. New trials are also being conducted on nanoparticles to enhance RT delivery. Hafnium oxide nanoparticles NBTXR3 are activated by RT to improve radiation-induced abscopal effects. These technologies are likely to improve the effects of neoadjuvant RT for patients with PDAC. Healthcare professionals will have the tools to deliver highly effective doses of RT without the tissue toxicity that currently limits the treatment potential of this therapy.For patients eligible for surgery, advances in surgical technology are improving -Abstract Truncated-

History of preoperative therapy for pancreatic cancer and the MD Anderson experience

Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Preoperative therapy for pancreatic adenocarcinoma—precision beyond anatomy

Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

Neoadjuvant and Adjuvant Therapy in Resectable Pancreatic Adenocarcinoma

Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer

Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how

Effect of Neoadjuvant Radiotherapy on Survival of Non-Metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis

Neoadjuvant treatment for pancreatic cancer: Controversies and advances

Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases

Trends and Outcomes of Neoadjuvant Chemotherapy for Clinical Stage T1 Pancreatic Cancer

Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater

Surgical management of pancreatic ductal adenocarcinoma: a narrative review

Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection

Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma

Pancreaticoduodenectomy after neoadjuvant chemotherapy for gastric cancer invading the pancreatic head: A case report

Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma

Editorial: Technological innovations and pancreatic cancer